Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use

Magnetic Resonance in Medical Sciences

Volumn 12, Issue 4, 2013, Pages 297-304

  Matsumura, Toru ^a   Hayakawa, Masakane ^a   Shimada, Fumiki ^a   Yabuki, Masahisa ^a   Dohanish, Susan ^b   Palkowitsch, Petra ^c   Yoshikawa, Kohki ^d  

^a BAYER YAKUHIN LTD   (Japan)

^b BAYER CORPORATION   (United States)

^c BAYER PHARMA AG   (Germany)

^d KOMAZAWA UNIVERSITY   (Japan)

Author keywords

Adverse event; Gadopentetate dimeglumine; Magnetic resonance imaging; MR contrast media; Safety

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

ARTICLE; DRUG SURVEILLANCE PROGRAM; DRUG USE; EUROPE; HUMAN; INTERNATIONAL COOPERATION; JAPAN; LONGITUDINAL STUDY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REGISTER; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

CONTRAST MEDIA; DRUG UTILIZATION REVIEW; EUROPE; GADOLINIUM DTPA; HUMANS; INTERNATIONALITY; JAPAN; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; PHARMACOVIGILANCE; REGISTRIES; UNITED STATES;

EID: 84891550752     PISSN: 13473182     EISSN: 18802206     Source Type: Journal    
DOI: 10.2463/mrms.2013-0020     Document Type: Article

References (26)

1. DeMarco JK, Willinek WA, Finn JP, Huston J, 3rd. Current state-of-the-art 1. 5T and 3T extracranial carotid contrast-enhanced magnetic resonance angiography. Neuroimaging ClinNAm2012; 22: 235-257.
2. Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology 2011; 260: 446-453.
3. Seo HJ, Kim MJ, Lee JD, Chung WS, Kim YE. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol 2011; 46: 548-555.
4. Messiou C, Orton M, Ang JE, et al. Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity. Radiology 2012; 265: 426-436.
5. Scardapane A, Stabile Ianora A, Sabbaà C, et al. Dynamic 4D MR angiography versus multislice CT angiography in the evaluation of vascular hepatic involvement in hereditary haemorrhagic telangiec tasia. Radiol Med 2012; 117: 29-45.
6. Friedman SN, Bambrough PJ, Kotsarini C, Khandanpour N, Hoggard N. Semi-automated and automated glioma grading using dynamic susceptibility-weighted contrast-enhanced perfusion MRI relative cerebral blood volume measurements. Br J Radiol 2012; 85: e1204-e1211.
7. Azuma T, Kodama T, Yano T, Suzuki M, Kimura T, Tamaribuchi Y. Improved visualization of intracranial vessels by gradient moment nulling in hybrid of opposite-contrast magnetic resonance angiography (HOP MRA). Magn Reson Med Sci 2010; 9: 159-165.
8. Cheng KT, Cheng HY, Leung K. Clinical use of gadobutrol for contrast-enhanced magnetic resonance imaging of neurological diseases. Reports in Medical Imaging 2012; 2012: 15-22.
9. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175: 621-628.
10. Schild HH, Kuhl CK, Hübner-Steiner U, Bö hm I, Speck U. Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial. Radiology 2006; 240: 56-64.
11. Grobner T. Gadolinium-a speciffi trigger for the development of nephrogeniffibrosing dermopathy and nephrogenic systemiffibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108.
12. World Health Organization. Pharmacovigilance: ensuring the safe use of medicines-WHO policy perspectives on medicines. October 2004; No. 009. Availableat: http://www. who. int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/. Accessed 28 February 2013.
13. Niendorf HP, Alhassan A, Geens VR, Clauss W. Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications. Invest Radiol 1994; 29 Suppl 2: S179-S182.
14. Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 1991; 22: 222-228.
15. Niendorf HP, Alhassan A, Balzer TH, Clauss W, Geens VR. Safety and risk of gadolinium-DTPA: extended clinical experience after more than 20 million applications. Magnevist Monograph. 3rd ed. Oxford: Blackwell Science, 1998: 17-27.
16. Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006; 41: 491-499.
17. Niendorf HP, Michel A, Lowe A, Dohanish S, Balzer T. Safety and risk of gadolinium-DTPA: extended clinical experience after more than 69 million applications. In: Lemke A-J, Niehues SM, Felix R, et al, eds. Magnevist Monograph. 5th ed. Oxford: Blackwell, 2007; 29-37.
18. Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008; 64: 743-752.
19. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances inInflammation Research. New York: Raven Press. 1984; 1-7.
20. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004; 24: 743-749.
21. Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 1991; 84: 341-344.
22. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-396.
23. Heinz-Peer G, Neruda A, Watschinger B, et al. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur J Radiol 2010; 76: 129-134.
24. Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson imaging 2009; 30: 1298-1308.
25. Tsushima Y, Kanal E, Thomsen HS. Nephrogenic systemiffibrosis: risk factors suggested from Japanese published cases. Br J Radiol 2010; 83: 590-595.
26. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemiffibrosis. Eur J Radiol 2008; 66: 191-199.